Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
0.9062
-0.0439 (-4.62%)
At close: Jun 23, 2025, 4:00 PM
0.9179
+0.0117 (1.29%)
After-hours: Jun 23, 2025, 7:15 PM EDT

Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $54.06 million. The enterprise value is $12.27 million.

Market Cap 54.06M
Enterprise Value 12.27M

Important Dates

The next estimated earnings date is Friday, August 15, 2025, before market open.

Earnings Date Aug 15, 2025
Ex-Dividend Date n/a

Share Statistics

Opus Genetics has 59.66 million shares outstanding. The number of shares has increased by 29.23% in one year.

Current Share Class 59.66M
Shares Outstanding 59.66M
Shares Change (YoY) +29.23%
Shares Change (QoQ) +11.61%
Owned by Insiders (%) 4.09%
Owned by Institutions (%) 27.81%
Float 49.74M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.93
Forward PS 3.68
PB Ratio 8.12
P/TBV Ratio 10.66
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 0.90
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.98

Current Ratio 1.98
Quick Ratio 1.92
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -26.45

Financial Efficiency

Return on equity (ROE) is -167.55% and return on invested capital (ROIC) is -64.84%.

Return on Equity (ROE) -167.55%
Return on Assets (ROA) -45.36%
Return on Invested Capital (ROIC) -64.84%
Return on Capital Employed (ROCE) -151.76%
Revenue Per Employee $758,389
Profits Per Employee -$3.26M
Employee Count 18
Asset Turnover 0.27
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -42.65% in the last 52 weeks. The beta is 0.29, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y) 0.29
52-Week Price Change -42.65%
50-Day Moving Average 0.93
200-Day Moving Average 1.09
Relative Strength Index (RSI) 40.13
Average Volume (20 Days) 2,383,650

Short Selling Information

The latest short interest is 154,728, so 0.26% of the outstanding shares have been sold short.

Short Interest 154,728
Short Previous Month 233,621
Short % of Shares Out 0.26%
Short % of Float 0.31%
Short Ratio (days to cover) 3.44

Income Statement

In the last 12 months, Opus Genetics had revenue of $13.65 million and -$58.62 million in losses. Loss per share was -$2.02.

Revenue 13.65M
Gross Profit -16.35M
Operating Income -36.30M
Pretax Income n/a
Net Income -58.62M
EBITDA -36.27M
EBIT -36.30M
Loss Per Share -$2.02
Full Income Statement

Balance Sheet

The company has $41.79 million in cash and n/a in debt, giving a net cash position of $41.79 million or $0.70 per share.

Cash & Cash Equivalents 41.79M
Total Debt n/a
Net Cash 41.79M
Net Cash Per Share $0.70
Equity (Book Value) 23.92M
Book Value Per Share 0.11
Working Capital 23.68M
Full Balance Sheet

Cash Flow

Operating Cash Flow -28.85M
Capital Expenditures n/a
Free Cash Flow -28.85M
FCF Per Share -$0.48
Full Cash Flow Statement

Margins

Gross Margin -119.74%
Operating Margin -265.88%
Pretax Margin -429.42%
Profit Margin n/a
EBITDA Margin -265.72%
EBIT Margin -265.88%
FCF Margin n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -29.23%
Shareholder Yield -29.23%
Earnings Yield -108.43%
FCF Yield -53.37%

Analyst Forecast

The average price target for Opus Genetics is $6.33, which is 598.52% higher than the current price. The consensus rating is "Strong Buy".

Price Target $6.33
Price Target Difference 598.52%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) 33.07%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Opus Genetics has an Altman Z-Score of -4.93 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -4.93
Piotroski F-Score 1